Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 724 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Home Is Where the Heart Is November 8, 2019 ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy October 20, 2023 6 of the biggest good news cancer stories of 2021 December 15, 2021 Dr Ian Walker on Smoking: ‘The killer behind the counter’ March 17, 2023 Load more HOT NEWS When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... Only a Quarter of Phase III Studies Demonstrated Improved QoL in... Why consistent and funded cancer policies are key to improving cancer... ESMO World Congress on Gastrointestinal Cancer 2020
